338 related articles for article (PubMed ID: 34226688)
21. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.
Kompella UB; Amrite AC; Pacha Ravi R; Durazo SA
Prog Retin Eye Res; 2013 Sep; 36():172-98. PubMed ID: 23603534
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic and diagnostic applications of nanoparticles.
Youns M; Hoheisel JD; Efferth T
Curr Drug Targets; 2011 Mar; 12(3):357-65. PubMed ID: 20955146
[TBL] [Abstract][Full Text] [Related]
23. Nanomedicines: The magic bullets reaching their target?
Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
[TBL] [Abstract][Full Text] [Related]
24. Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery.
Waheed S; Li Z; Zhang F; Chiarini A; Armato U; Wu J
J Nanobiotechnology; 2022 Aug; 20(1):395. PubMed ID: 36045386
[TBL] [Abstract][Full Text] [Related]
25. Progress and challenges in the translation of cancer nanomedicines.
Tong F; Wang Y; Gao H
Curr Opin Biotechnol; 2024 Feb; 85():103045. PubMed ID: 38096768
[TBL] [Abstract][Full Text] [Related]
26. Smart Nanosystems for Overcoming Multiple Biological Barriers in Cancer Nanomedicines Transport: Design Principles, Progress, and Challenges.
Lin G; Zhou J; Cheng H; Liu G
Small; 2023 Jul; 19(28):e2207973. PubMed ID: 36971279
[TBL] [Abstract][Full Text] [Related]
27. New Strategies in the Design of Nanomedicines to Oppose Uptake by the Mononuclear Phagocyte System and Enhance Cancer Therapeutic Efficacy.
Zhou Y; Dai Z
Chem Asian J; 2018 Nov; 13(22):3333-3340. PubMed ID: 29441706
[TBL] [Abstract][Full Text] [Related]
28. Insights into Active Targeting of Nanoparticles in Drug Delivery: Advances in Clinical Studies and Design Considerations for Cancer Nanomedicine.
Pearce AK; O'Reilly RK
Bioconjug Chem; 2019 Sep; 30(9):2300-2311. PubMed ID: 31441642
[TBL] [Abstract][Full Text] [Related]
29. Nanomedicines for developing cancer nanotherapeutics: from benchtop to bedside and beyond.
Iqbal J; Abbasi BA; Ahmad R; Mahmood T; Ali B; Khalil AT; Kanwal S; Shah SA; Alam MM; Badshah H; Munir A
Appl Microbiol Biotechnol; 2018 Nov; 102(22):9449-9470. PubMed ID: 30219952
[TBL] [Abstract][Full Text] [Related]
30. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X
AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932
[TBL] [Abstract][Full Text] [Related]
31. Pulmonary delivery nanomedicines towards circumventing physiological barriers: Strategies and characterization approaches.
Wang W; Huang Z; Huang Y; Zhang X; Huang J; Cui Y; Yue X; Ma C; Fu F; Wang W; Wu C; Pan X
Adv Drug Deliv Rev; 2022 Jun; 185():114309. PubMed ID: 35469997
[TBL] [Abstract][Full Text] [Related]
32. Safety assessment of nanomaterials: implications for nanomedicine.
Nyström AM; Fadeel B
J Control Release; 2012 Jul; 161(2):403-8. PubMed ID: 22306428
[TBL] [Abstract][Full Text] [Related]
33. Engineering a Nano/Biointerface for Cell and Organ-Selective Drug Delivery.
Song D; Xu Q
Langmuir; 2022 Aug; 38(30):9092-9098. PubMed ID: 35852946
[TBL] [Abstract][Full Text] [Related]
34. Nanomedicine in cancer therapy.
Fan D; Cao Y; Cao M; Wang Y; Cao Y; Gong T
Signal Transduct Target Ther; 2023 Aug; 8(1):293. PubMed ID: 37544972
[TBL] [Abstract][Full Text] [Related]
35. Not just for tumor targeting: unmet medical needs and opportunities for nanomedicine.
Lepeltier EA; Nuhn L; Lehr CM; Zentel R
Nanomedicine (Lond); 2015; 10(20):3147-66. PubMed ID: 26447353
[TBL] [Abstract][Full Text] [Related]
36. Carrier-Free Nanomedicine for Cancer Immunotherapy.
Fu Y; Bian X; Li P; Huang Y; Li C
J Biomed Nanotechnol; 2022 Apr; 18(4):939-956. PubMed ID: 35854464
[TBL] [Abstract][Full Text] [Related]
37. Advances, challenge and prospects in cell-mediated nanodrug delivery for cancer therapy: a review.
Wei W; Zhang Y; Lin Z; Wu X; Fan W; Chen J
J Drug Target; 2023 Jan; 31(1):1-13. PubMed ID: 35857432
[TBL] [Abstract][Full Text] [Related]
38. Bridging Bio-Nano Science and Cancer Nanomedicine.
Björnmalm M; Thurecht KJ; Michael M; Scott AM; Caruso F
ACS Nano; 2017 Oct; 11(10):9594-9613. PubMed ID: 28926225
[TBL] [Abstract][Full Text] [Related]
39. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
Patel P; Shah J
Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
[TBL] [Abstract][Full Text] [Related]
40. Surface-Engineered Cancer Nanomedicine: Rational Design and Recent Progress.
Ahmad J; Ameeduzzafar ; Ahmad MZ; Akhter H
Curr Pharm Des; 2020; 26(11):1181-1190. PubMed ID: 32056517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
